<DOC>
	<DOCNO>NCT01392729</DOCNO>
	<brief_summary>This prospective observational study evaluate efficacy safety Avastin ( bevacizumab ) combination interferon alpha 2a patient previously untreated metastatic renal cell cancer . Data collect patient 4 year .</brief_summary>
	<brief_title>An Observational Study Avastin ( Bevacizumab ) Interferon Alpha 2a Patients With Metastatic Renal Cell Cancer ( VERA )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Histologically confirm metastatic renal cell cancer , clear cell type Eligible treatment Avastin interferon alpha 2a accord local prescribing information Contraindications Avastin interferon alpha 2a treatment accord local Summary Product Characteristics Known hypersensitivity Avastin and/or interferon alpha 2a excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>